Researchers link organ-transplant drug to increased cancer risk

06/28/2010 | HealthDay News

A Dutch study showed that organ-rejection drug cyclosporine significantly increased the risk of cancer in patients younger than 50 who had a liver transplant between 1986 and 2007, particularly those who more recently underwent the procedure. Researchers also found that cyclosporine treatment was more likely than standard therapy tacrolimus to result in a more aggressive type of cancer.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN